Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 23,187 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock in a transaction on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.
• On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.13, for a total value of $662,250.96.
• On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40.
• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00.
• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89.

Hims & Hers Health Stock Down 1.2%

Shares of Hims & Hers Health stock traded down $0.45 on Wednesday, hitting $35.81. The company had a trading volume of 20,738,539 shares, compared to its average volume of 32,329,717. The stock has a 50-day moving average of $50.12 and a 200-day moving average of $51.42. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims & Hers Health, Inc. has a twelve month low of $21.36 and a twelve month high of $72.98. The firm has a market capitalization of $8.15 billion, a P/E ratio of 66.31, a P/E/G ratio of 7.08 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company’s revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has approved a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. grew its stake in shares of Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after buying an additional 2,128,587 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health in the first quarter valued at $58,403,000. Clear Street LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $83,582,000. Finally, Norges Bank acquired a new position in Hims & Hers Health during the 2nd quarter worth about $78,464,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HIMS. UBS Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, November 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research report on Tuesday, November 4th. Finally, Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $45.27.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.